Compare Elder Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA LUPIN ELDER PHARMA/
LUPIN
 
P/E (TTM) x -0.2 48.9 - View Chart
P/BV x 0.1 2.5 4.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   LUPIN
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
LUPIN
Mar-19
ELDER PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs380986 38.5%   
Low Rs188720 26.1%   
Sales per share (Unadj.) Rs491.2369.5 132.9%  
Earnings per share (Unadj.) Rs-3.213.4 -23.7%  
Cash flow per share (Unadj.) Rs14.437.4 38.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.5303.7 124.0%  
Shares outstanding (eoy) m20.54452.49 4.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.62.3 25.0%   
Avg P/E ratio x-89.363.6 -140.2%  
P/CF ratio (eoy) x19.722.8 86.4%  
Price / Book Value ratio x0.82.8 26.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,833386,064 1.5%   
No. of employees `000NA17.7 0.0%   
Total wages/salary Rs m2,17931,513 6.9%   
Avg. sales/employee Rs ThNM9,453.8-  
Avg. wages/employee Rs ThNM1,782.0-  
Avg. net profit/employee Rs ThNM343.0-  
INCOME DATA
Net Sales Rs m10,089167,182 6.0%  
Other income Rs m2573,640 7.0%   
Total revenues Rs m10,346170,822 6.1%   
Gross profit Rs m-79228,822 -2.7%  
Depreciation Rs m36110,850 3.3%   
Interest Rs m2,7563,078 89.5%   
Profit before tax Rs m-3,65318,534 -19.7%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m3,713-3,400 -109.2%   
Tax Rs m1259,017 1.4%   
Profit after tax Rs m-656,066 -1.1%  
Gross profit margin %-7.817.2 -45.5%  
Effective tax rate %-3.448.7 -7.0%   
Net profit margin %-0.63.6 -17.9%  
BALANCE SHEET DATA
Current assets Rs m9,240138,536 6.7%   
Current liabilities Rs m9,99861,299 16.3%   
Net working cap to sales %-7.546.2 -16.3%  
Current ratio x0.92.3 40.9%  
Inventory Days Days4684 55.3%  
Debtors Days Days60112 53.3%  
Net fixed assets Rs m10,124127,516 7.9%   
Share capital Rs m206905 22.7%   
"Free" reserves Rs m5,582136,517 4.1%   
Net worth Rs m7,734137,422 5.6%   
Long term debt Rs m4,88966,417 7.4%   
Total assets Rs m22,882279,494 8.2%  
Interest coverage x-0.37.0 -4.6%   
Debt to equity ratio x0.60.5 130.8%  
Sales to assets ratio x0.40.6 73.7%   
Return on assets %11.83.3 359.5%  
Return on equity %-0.84.4 -19.1%  
Return on capital %22.38.9 250.4%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30759,414 0.5%   
Fx outflow Rs m12522,282 0.6%   
Net fx Rs m18137,132 0.5%   
CASH FLOW
From Operations Rs m11,75416,660 70.6%  
From Investments Rs m-561-32,825 1.7%  
From Financial Activity Rs m-6,7627,441 -90.9%  
Net Cashflow Rs m4,432-8,724 -50.8%  

Share Holding

Indian Promoters % 39.6 46.6 85.0%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.5 11.3 66.4%  
FIIs % 16.8 31.9 52.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 10.1 357.4%  
Shareholders   16,479 98,259 16.8%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS